Biomaterials manufacturer Collagen Solutions has declared it is on track to meet market forecasts for the year as it booked a first-half loss of £1.06 million.
The Glasgow-based firm said pre-tax losses narrowed from £1.38m for the same period last year in its interim results for the six months ended September 30, 2018.
The company highlighted new distribution agreements in Europa and Asia and the progress of restructuring its New Zealand operation, which is seeing it consolidate manufacturing in Scotland.
While one significant Asia Pacific contract has ended, sales in North America have grown by 86 per cent to £1.45m.
Jamal Rushdy, Collagen chief executive, said: "We are very pleased with our commercial and financial results in the first six months.
"Revenue came in at £2.1m, representing 13% growth.
"The reason that is significant is that it is inclusive of a contract termination we talked about last year of a South Korean customer supply agreement.
"That agreement has expired until they are ready to re-order again, so, despite that downturn, we grew by 13%."
Read more: More takeovers on horizon for Glasgow cloud computing firm
He said: "If you take that out we actually grew 55%, so the commercial organisation has done a fantastic job of not only sourcing deals but executing on prior opportunities that we had in the pipeline for a while and we see a lot of new business coming through."
Nine new customers against eight for the same period last year is the company's best batch of new deals over six months to date.
Mr Rushdy said: "The other headline is that we are happy with new business initiatives.
"On the tissue side, we have diversified our tissue species. We now offer different types of tissues.
"That has helped drive some of the new accounts we’ve got."
He said that "because of the long cycle of getting a new tissue customer on in terms of validation and so forth we expect that more" new business will come through "at the end of this year and moreso into next year".
Read more: China double as Collagen Solutions flags 13% revenue rise
The final submissions on ChondroMimetic, the company's collagen-based implant for the treatment of small cartilage and underlying bone defects, are due for market approval.
Mr Rushdy said: "We’ve been in consultation for a while so we don’t expect any surprises. We will see."
He declared: "Financially, from a revenue perspective, we’re on track, from a margins perspective, we’re actually a little ahead of where we thought we were going to be, as we are with cash.
"Revenue, margins and cash have all come together to put us in a very good position for the first six months and a good position for hitting our expectations for this full year."
Read more: Russia 'challenging' and weakness in Japan for Devro as chairman steps down
The North America results came after a sales push.
Mr Rushdy said: "A lot of the deals we’ve been working on happen in the North American market - in fact most of the development deals - and these will then translate into contract manufacturing out of Scotland to supply the North American market once those products get approved, so it has been a focus of ours to grow North America."
Hilary Spence, Collagen chief financial officer, said: "We want to be part of Scotland’s life sciences aspirations and we are very much hooked into growing the business in Scotland. It’s great for the Scottish economy."
Collagen was initially formed as part of Glasgow sausage skin maker Devro in 2008, and develops, manufactures and supplies medical grade biomaterials for research, medical devices and regenerative medicine.
Shares closed up 1.5% at 3.3p.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here